Page last updated: 2024-10-26

diclofenac and B-Cell Lymphoma

diclofenac has been researched along with B-Cell Lymphoma in 1 studies

Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.

Research Excerpts

ExcerptRelevanceReference
"Diclofenac was started at a median of 20 hours (range 13-33) after fever onset."5.72Cytokine release syndrome after CAR infusion in pediatric patients with refractory/relapsed B-ALL: is there a role for diclofenac? ( Balduzzi, A; Bettini, L; Biondi, A; Bonanomi, S; Napolitano, S; Ottaviano, G; Rona, R; Rovelli, A; Russotto, V, 2022)
"Diclofenac was started at a median of 20 hours (range 13-33) after fever onset."1.72Cytokine release syndrome after CAR infusion in pediatric patients with refractory/relapsed B-ALL: is there a role for diclofenac? ( Balduzzi, A; Bettini, L; Biondi, A; Bonanomi, S; Napolitano, S; Ottaviano, G; Rona, R; Rovelli, A; Russotto, V, 2022)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Napolitano, S1
Ottaviano, G1
Bettini, L1
Russotto, V1
Bonanomi, S1
Rovelli, A1
Biondi, A1
Rona, R1
Balduzzi, A1

Other Studies

1 other study available for diclofenac and B-Cell Lymphoma

ArticleYear
Cytokine release syndrome after CAR infusion in pediatric patients with refractory/relapsed B-ALL: is there a role for diclofenac?
    Tumori, 2022, Volume: 108, Issue:6

    Topics: Child; Cytokine Release Syndrome; Diclofenac; Humans; Immunotherapy, Adoptive; Lymphoma, B-Cell; Pre

2022